SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil is excited to support the establishment of the Associação Nacional dos usuários de Canabidiol (ANUC) Patient Association in Brazil dedicated to connecting patients with cannabis-friendly doctors and continuing to educate the Brazilian medical community and its citizens on the therapeutic uses of cannabis. The Company also applauds the appointment of Franklin Vargas as President of the Patient Association.
This new Patient Association in Brazil will offer educational courses on the medical value and therapeutic uses of cannabis, introduce potential cannabis patients to cannabis-friendly doctors and coordinate efforts to donate cannabis products to patients who cannot afford them.
"We are excited about the opportunities the establishment of this new ANUC Patient Association will afford to educate a broader number of Brazilian citizens on the plethora of benefits that medical cannabis provides to treat several types of indications, as well as connecting them with doctors that can help," said Chief Executive Officer of Medical Marijuana, Inc. Dr. Stuart Titus. "Brazil is a major market for our Organization and we continue to be impressed with the response of the Country's health authority in their proactive measures to see that products like ours get to those who need it most and the increasing interest health professionals are showing in how they can prescribe CBD hemp oil products to their patients."
ANUC Patient Association President, Mr. Vargas, whose niece has been taking the Company's hemp CBD oil product Real Scientific Hemp Oil™ (RSHO™) for the past three years to treat her epileptic seizures, said: "HempMeds® Brasil has been instrumental in creating access to medical cannabis in Brazil, and helping treat patients like my niece who suffer from debilitating medical conditions. I am honored to take on this new responsibility as President of the Patient Association, which I believe will help bring relief to more and more families across Brazil with our focus on education and connecting citizens to doctors that can help."
HempMeds Brasil™ is the first company to offer legal medicinal cannabis products to Brazil after receiving import approval to those suffering from specific medical conditions. Most recently in February 2017, for the filling of a prescription for the first time for the Company's hemp CBD oil product RSHO™ to treat patients in the Country suffering from Multiple Sclerosis. Additionally, doctors in Brazil can prescribe RSHO™ for any condition and HempMeds Brasil™ has worked with several cases including patients suffering from:
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically-sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
About HempMeds® Brasil
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for multiple conditions including; Epilepsy, Parkinson's, Chronic Pain, Psoriasis, Cancer, Alzheimer's, Diabetes, ALS, Multiple Sclerosis and Migraines. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.